Compare SPRO & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | INO |
|---|---|---|
| Founded | 2013 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 114.0M |
| IPO Year | 2017 | 1999 |
| Metric | SPRO | INO |
|---|---|---|
| Price | $2.34 | $1.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 251.4K | ★ 624.8K |
| Earning Date | 03-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | 54.18 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $66,802,000.00 | $42,220,086.00 |
| Revenue This Year | N/A | $24,407.60 |
| Revenue Next Year | N/A | $331.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.24 | 19.37 |
| 52 Week Low | $0.51 | $1.30 |
| 52 Week High | $3.09 | $2.86 |
| Indicator | SPRO | INO |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 44.05 |
| Support Level | $2.31 | $1.48 |
| Resistance Level | $2.44 | $1.78 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 11.90 | 35.19 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.